Title:
組換え抗上皮増殖因子受容体抗体組成物
Document Type and Number:
Japanese Patent JP5719298
Kind Code:
B2
Abstract:
The invention relates to the field of recombinant antibodies for use in human cancer therapy. More specifically the invention provides the use of an antibody composition with two distinct non-overlapping binding specificities to human EGFR. The antibody composition is effecting in treating cancer following treatment with other anti-EGFR antibodies, whether the cancer shows progression during or following the prior treatment or not. The antibody composition can also be used for repeated treatment of recurrent tumors following first-line therapy with the antibody composition of the invention, as the composition does not lead to selection of resistant tumors. A further therapeutic use is the use of an antibody composition of the invention for treatment of cancer that is resistant to known anti-EGFR antibodies.
Inventors:
Mickel Wanderle Pedersen
Michael Krug
Adam S. Hay
Helle Jacobsen
Michael Krug
Adam S. Hay
Helle Jacobsen
Application Number:
JP2011524186A
Publication Date:
May 13, 2015
Filing Date:
August 27, 2009
Export Citation:
Assignee:
SYMPHOGEN A/S
International Classes:
A61K39/395; A61P35/00
Domestic Patent References:
| JP2010535012A | ||||
| JP2006505546A |
Attorney, Agent or Firm:
Mitsuo Tanaka
Hiroshi Yamazaki
Kenji Tomita
Masayuki Nakagawa
Fumio Inai
Manami Sasakura
Hiroshi Yamazaki
Kenji Tomita
Masayuki Nakagawa
Fumio Inai
Manami Sasakura